GENFIT overview

All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortly Upon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 OCEANEs and pay the Consent Fee Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver...

Cash and cash equivalents totaled €81.8 million as of December 31, 2024 Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of...

2 new ACLF clinical trials expected to initiate in 1Q25 3 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trial Data of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company...

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments Proceeds to further strengthen the development of the ACLF...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial . Under the liquidity contract GENFIT has with Crédit Industriel et Commercial , the following resources appeared on the liquidity...

PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024 Launch of Iqirvo® (elafibranor) 1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S. UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024 Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in Europe Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4...

Cash and cash equivalents totaled €96.0 million as of September 30, 2024 €59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the European Commission has conditionally approved Iqirvo® 1 (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an...